Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 15/20 | 0.61 |
| ▸ | STAT3 | P40763 | 1/20 | 0.61 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | JAK1 | P23458 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30349558 | 1.00 | TYK2 (0.61) | TYK2STAT3PDE4DSMN1; SMN2MAPT | |
| SCHEMBL21887788 | 0.92 | TYK2 (0.53) | TYK2STAT3PDE4DSMN1; SMN2ALOX15 | |
| SCHEMBL21887328 | 0.88 | TYK2 (0.66) | TYK2STAT3PDE4DJAK1 | |
| SCHEMBL21887349 | 0.86 | TYK2 (0.69) | TYK2STAT3PDE4DJAK1 | |
| SCHEMBL30349340 | 0.86 | ADORA3 (0.48) | TYK2STAT3SMN1; SMN2MAPTUSP2 | |
| SCHEMBL30349550 | 0.83 | TYK2 (0.60) | TYK2STAT3PDE4DMAPT | |
| SCHEMBL21811202 | 0.83 | TYK2 (0.60) | TYK2STAT3PDE4DMAPT | |
| SCHEMBL21887357 | 0.82 | TYK2 (0.58) | TYK2STAT3PDE4DJAK1 | |
| SCHEMBL22343246 | 0.81 | TYK2 (0.49) | TYK2PDE4DSMN1; SMN2JAK1KDM4E | |
| SCHEMBL24961657 | 0.81 | TYK2 (0.55) | TYK2STAT3PDE4DMAPTJAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11891400-B2 | Pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives useful in the treatment of psoriasis and systemic lupus erythematosus | ELI LILLY AND COMPANY (US) | 2024-02-06 | — | — | US | disclosed |
| EP-3849981-B1 | PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSORIASIS AND SYSTEMIC LUPUS ERYTHEMATOSUS | LILLY CO ELI (US) | 2023-02-01 | — | — | EP | disclosed |
| EP-3849981-B1 | PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSORIASIS AND SYSTEMIC LUPUS ERYTHEMATOSUS | LILLY CO ELI (US) | 2023-02-01 | — | — | EP | disclosed |
| EP-3849981-A1 | PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSORIASIS AND SYSTEMIC LUPUS ERYTHEMATOSUS | Eli Lilly and Company (US) | 2021-07-21 | — | — | EP | disclosed |
| US-20210188861-A1 | PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSORIASIS AND SYSTEMIC LUPUS ERYTHEMATOSUS | ELI LILLY AND COMPANY | 2021-06-24 | — | — | US | disclosed |
| US-20210188861-A1 | PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSORIASIS AND SYSTEMIC LUPUS ERYTHEMATOSUS | ELI LILLY AND COMPANY | 2021-06-24 | — | — | US | disclosed |
| WO-2020055636-A1 | PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSORIASIS AND SYSTEMIC LUPUS ERYTHEMATOSUS | ELI LILLY AND COMPANY (US) | 2020-03-19 | — | — | WO | disclosed |
| WO-2020055636-A1 | PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSORIASIS AND SYSTEMIC LUPUS ERYTHEMATOSUS | ELI LILLY AND COMPANY (US) | 2020-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891400-B2 | Pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives useful in the treatment of psoriasis and systemic lupus erythematosus | SSB, TPMT, SPHK1 | TYK2 140/4885STAT3 787/4885PDE4D 661/4885 |
| US-20210188861-A1 | PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSORIASIS AND SYSTEMIC LUPUS ERYTHEMATOSUS | SSB, TPMT, SPHK1 | TYK2 140/4885STAT3 787/4885PDE4D 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.